Joseph La Torre
Biographic Data
| ID | 1851504 |
|---|---|
| NAME | Joseph La Torre |
| GIVEN NAMES | Joseph |
| FAMILY NAME | La Torre |
| SIGNATURE | LA TORRE J |
| AFFILIATIONS | University of Ottawa |
| ORCID | 0000-0002-0260-1438 |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 1 |
| AUTHOR COUNT | 6 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
A qualitative study of long-term members of ayahuasca spiritual communities in the United States
This novel qualitative study examines the lived experiences of long-term participants in ayahuasca spiritual communities (ASCs) in the United States. Semi-structured interviews ( n = 11) were analyzed using reflexive thematic analysis indicating that these communities (1) attract individuals seeking healing from trauma, addiction, and psychological distress, while offering a sense of belonging and cultural identity; (2) integrate Western biomedic…
Small doses, big questions
Experiences of psychedelic drug use among people with psychotic symptoms and disorders
Individuals with a history of psychotic experiences and disorders such as schizophrenia, and mood disorders with psychotic features tend to be excluded from psychedelic-assisted therapy research and treatment programs, despite minimal research demonstrating heightened risk of adverse effects for this group. Participants (n = 100) were asked to complete an online, retrospective survey that asked about psychotic experiences and/or diagnoses and one…
The mushroom was more alive and vibrant
Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such as MDMA, ketamine, DMT, LSD, ibogaine, and psilocybin. To date, few clinical trials have utilized whole mushroom/plant material like Psilocybe mushrooms, Iboga, or Ayahuasca. Individuals participating in the Roots To Thrive Psilocybin-Assisted Therapy for End of Life Distress program were administered syntheti…
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders
Healing Words
Psychedelic-assisted psychotherapy (PAP) is gaining renewed interest as a treatment for various mental disorders. However, there has been limited Black, Indigenous, and People of Color (BIPOC) representation in PAP clinical trials, signaling the need for culturally consonant communication about the efficacy and safety of PAP. We randomly assigned 321 BIPOC and 301 non-Hispanic White participants to four different modes of psychoeducation (didacti…
Experiences of psychedelic drug use among people with psychotic symptoms and disorders
Individuals with a history of psychotic experiences and disorders such as schizophrenia, and mood disorders with psychotic features tend to be excluded from psychedelic-assisted therapy research and treatment programs, despite minimal research demonstrating heightened risk of adverse effects for this group. Participants (n = 100) were asked to complete an online, retrospective survey that asked about psychotic experiences and/or diagnoses and one…
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders
Healing Words
Psychedelic-assisted psychotherapy (PAP) is gaining renewed interest as a treatment for various mental disorders. However, there has been limited Black, Indigenous, and People of Color (BIPOC) representation in PAP clinical trials, signaling the need for culturally consonant communication about the efficacy and safety of PAP. We randomly assigned 321 BIPOC and 301 non-Hispanic White participants to four different modes of psychoeducation (didacti…
Experiences of psychedelic drug use among people with psychotic symptoms and disorders
Individuals with a history of psychotic experiences and disorders such as schizophrenia, and mood disorders with psychotic features tend to be excluded from psychedelic-assisted therapy research and treatment programs, despite minimal research demonstrating heightened risk of adverse effects for this group. Participants (n = 100) were asked to complete an online, retrospective survey that asked about psychotic experiences and/or diagnoses and one…
The mushroom was more alive and vibrant
Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such as MDMA, ketamine, DMT, LSD, ibogaine, and psilocybin. To date, few clinical trials have utilized whole mushroom/plant material like Psilocybe mushrooms, Iboga, or Ayahuasca. Individuals participating in the Roots To Thrive Psilocybin-Assisted Therapy for End of Life Distress program were administered syntheti…
A qualitative study of long-term members of ayahuasca spiritual communities in the United States
This novel qualitative study examines the lived experiences of long-term participants in ayahuasca spiritual communities (ASCs) in the United States. Semi-structured interviews ( n = 11) were analyzed using reflexive thematic analysis indicating that these communities (1) attract individuals seeking healing from trauma, addiction, and psychological distress, while offering a sense of belonging and cultural identity; (2) integrate Western biomedic…
Small doses, big questions
Psychedelics and Drug Studies (5 works) · Medicine (4 works) · Psychiatry (4 works) · Psychology (4 works) · Clinical Psychology (3 works) · Neurotransmitter Receptor Influence on Behavior (3 works) · Psychotherapist (3 works) · Clinical Psychology (2 works) · Mental health (2 works) · Qualitative research (2 works)